Bioresorbable scaffolds: past and present. Clinical example of a 10-year follow-up of a patient with an implanted Absorb stent
https://doi.org/10.52727/2078-256X-2024-20-2-173-182
Abstract
Today we can say with confidence that percutaneous coronary intervention is an effective, minimally invasive and safe method of treating coronary heart disease. As always complex problems require necessary solutions. One such challenge is the use of metallic covered stents because the stent frame remains permanently in the artery. The idea to create a bioresorbable scaffold appeared more than 20 years ago, and one of the pioneers was the Absorb scaffold, which was implanted in quantities of more than 150 000. During the existence of this stent, a large number of studies were carried out, strengths and weaknesses were identified and eventually came to the conclusion that it was discontinued, but creating Absorb gave a powerful drive to the invention of new types of scaffolds.
About the Authors
A. I. Zagorulko
State budgetary healthcare institution of the city of Moscow “Moscow city clinical oncological hospital № 1”; Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Alexei I. Zagorulko, MD, assistant, Head of department
Medical institute; department of cardiology, endovascular surgery and hybrid methods of diagnosis and treatment; department of endovascular surgery
117152; 18a, bldg. 7, Zagorodnoye highw.; 117198; 6, Miklukho-Maklaya str.; Moscow
M. V. Chernyaev
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Mikhail V. Chernyaev, candidate of medical sciences, MD, assistant
Medical institute; department of hospital surgery with a course in pediatric surgery
117198; 6, Miklukho-Maklaya str.; Moscow
A. G. Koledinskiy
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Anton G. Koledinskiy, doctor of medical sciences, head of the department
department of cardiology, endovascular surgery and hybrid methods of diagnosis and treatment endovascular surgery
117198; 6, Miklukho-Maklaya str.; Moscow
References
1. Serruys P.W., Ormiston J., van Geuns R.J., de Bruyne B., Dudek D., Christiansen E., Chevalier B., Smits P., McClean D., Koolen J., Windecker S., Whitbourn R., Meredith I., Wasungu L., Ediebah D., Veldhof S., Onuma Y. A polylactide bioresorbable scaffold eluting everolimus for treatment of coronary stenosis: 5-year follow-up. J. Am. Coll. Cardiol., 2016; 67: 766–776. doi: 10.1016/j.jacc.2015.11.060
2. Onuma Y., Dudek D., Thuesen L., Webster M., Nieman K., Garcia-Garcia H.M., Ormiston J.A., Serruys P.W. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc. Interv., 2013; 6: 999–1009. doi: 10.1016/j.jcin.2013.05.017
3. Brugaletta S., Radu M.D., Garcia-Garcia H.M., Heo J.H., Farooq V., Girasis C., Geuns R.J., Thuesen L., McClean D., Chevalier B., Windecker S., Koolen J., Rapoza R., Miquel-Hebert K., Ormiston J., Serruys P.W. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis, 2012; 221: 106–112. doi: 10.1016/j.atherosclerosis.2011.12.008
4. Brugaletta S., Heo J.H., Garcia-Garcia H.M., Farooq V., van Geuns R.J., de Bruyne B., Dudek D., Smits P., Koolen J., McClean D., Dorange C., Veldhof S., Rapoza R., Onuma Y., Bruining N., Ormiston J., Serruys P.W. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur. Heart. J., 2012; 33: 1325–1333. doi: 10.1016/j.amjcard.2012.01.071.
5. Zagorulko A.I., Sidelnikov A.V., Shevchuk I.V., Koledinsky A.G. The efficacy and safety of Absorb BVS bioresorbable scaffolds in treatment of coronary heart disease in patients with diabetes mellitus. Post-Qualifying Medical Education Herald. 2019; 4: 11–14. (In Russ.)
6. Ali Z.A., Serruys P.W., Kimura T., Gao R., Ellis S.G., Kereiakes D.J., Onuma Y., Simonton C., Zhang Z., Stone G.W. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. Lancet, 2017; 390: 760–772. doi: 10.1016/S0140-6736(17)31470-8
7. Ali Z.A., Gao R., Kimura T., Onuma Y., Kereiakes D.J., Ellis S.G., Chevalier B., Vu M.T., Zhang Z., Simonton C., Serruys P.W., Stone G. Three-year outcomes with the absorb bioresorbable scaffold: individual-patient-data meta-analysis from the ABSORB randomized trials. Circulation, 2018; 137: 464–479. doi: 10.1161/CIRCULATIONAHA.117.031843
8. Kereiakes D.J., Ellis S.G., Metzger D.C., Caputo R.P., Rizik D.G., Teirstein P.S., Litt M.R., Kini A., Kabour A., Marx S., Popma J.J., Tan H.T., Ediebah D., Simonton C., Stone G.W. ABSORB III Investigators. Clinical outcomes before and after complete everolimus-eluting bioresorbable scaffold resorption: five-year follow-up from the ABSORB III trial. Circulation, 2019; 140: 1895–1903. doi: 10.1161/CIRCULATIONAHA.119.042584
9. Kozuma K., Tanabe K., Hamazaki Y., Okamura T., Ando J., Ikari Y., Nakagawa Y., Kusano H., Ediebah D., Kimura T. ABSORB Japan Investigators. Long-term outcomes of absorb bioresorbable vascular scaffold vs. Everolimus-eluting metallic stent – a randomized comparison through 5 years in Japan. Circul. J., 2020; 84: 733–741. doi: 10.1253/circj.CJ-19-1184
10. Stone G.W., Kimura T., Gao R., Kereiakes D.J., Ellis S.G., Onuma Y., Chevalier B., Simonton C., Dressler O., Crowley A., Ali Z.A., Serruys P.W. Time-varying outcomes with the absorb bioresorbable vascular scaffold during 5-year follow-up: a systematic meta-analysis and individual patient data pooled study. JAMA Cardiol., 2019; 4: 1261–1269. doi: 10.1001/jamacardio.2019.4101
11. Verheye S., Ormiston J.A., Stewart J., Webster M., Sanidas E., Costa R., Chamie D., Abizaid A.S., Pinto I., Morrison L., Toyloy S., Bhat V., Yan J., Abizaid A. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. JACC Cardiovasc. Interv., 2014; 7: 89–99. doi: 10.1016/j.jcin.2013.07.007
12. Abizaid A., Costa R.A., Schofer J., Ormiston J., Maeng M., Witzenbichler B., Botelho R., Costa J.R., Chamié D., Abizaid A., Castro J. , Morrison L., Toyloy S., Vinayak Bhat V., Yan J., Verheye S. Serial multimodality imaging and 2-year clinical outcomes of the novel DESolve novolimus-eluting bioresorbable coronary scaffold system for the treatment of single de novo coronary lesions. JACC Cardiovasc. Interv., 2016; 9: 565–574. doi: 10.1016/j.jcin.2015.12.004
13. Nef H., Wiebe J., Boeder N., Dörr O., Bauer T., Hauptmann K.E., Latib A., Colombo A., Fischer D., Rudolph T., Foin N., Richardt G., Hamm C. A multicenter post-marketing evaluation of the Elixir DESolve(®) Novolimus-eluting bioresorbable coronary scaffold system: First results from the DESolve PMCF study. Catheterizat. Cardiovasc. Interv., 2018; 92: 1021–1027. doi: 10.1002/ccd.27550
14. Mattesini A., Boeder N., Valente S., Löblich K., Dörr O., Secco G.G., Foin N., Caiazzo G., Ghione M., Gensini G.F., Porto I., Mario C.D., Nef H. Absorb vs. DESolve: an optical coherence tomography comparison of acute mechanical performances. EuroIntervention. 2016; 12: e566–е573. doi: 10.4244/EIJV12I5A96
15. Mattesini A., Bartolini S., Sorini Dini C., Valente S., Parodi G., Stolcova M., Meucci F., Mario C.D. The DESolve novolimus bioresorbable scaffold: from bench to bedside. J. Thorac. Dis., 2017; 9 (Suppl. 9): S950–S958. doi: 10.21037/jtd.2017.07.25
16. Abizaid A., Carrié D., Frey N., Lutz M., Weber-Albers J., Dudek D., Chevalier B., Weng S., Costa R., Anderson J., Stone G.W.; FANTOM II Clinical Investigators. 6-month clinical and angiographic outcomes of a novel radiopaque sirolimus-eluting bioresorbable vascular scaffold: the FANTOM II Study. JACC Cardiovasc. Interv., 2017; 10: 1832–1838. doi: 10.1016/j.jcin.2017.07.033
17. Simonsen J.K., Holck E.N., Carrié D., Frey N., Lutz M., Weber-Albers J., Dudek D., Daemen J., Dijkstra J., Maule C.F., Neghabat O., Lassen J.F., Anderson J., Christiansen E.H., Abizaid A., Ramsing Holm N.R. Mechanical performance and healing patterns of the novel sirolimus-eluting bioresorbable Fantom scaffold: 6-month and 9-month follow-up by optical coherence tomography in the FANTOM II study. Open Heart, 2019; 6:e000941. doi: 10.1136/openhrt-2018-000941
18. Waksman R., Lipinski M.J., Acampado E., Cheng Q., Adams L., Torii S., Gai J., Torguson R., Hellinga D., Joner M., Harder C., Zumstein P., Finn A.V., Kolodgie F.D., Virmani R., Waksman R. Comparison of acute thrombogenicity for metallic and polymeric bioabsorbable scaffolds: magmaris versus absorb in a porcine arteriovenous shunt model. Circul. Cardiovasc. Interv., 2017; 10: e004762. doi: 10.1161/CIRCINTERVENTIONS.116.004762
19. Erbel R., di Mario C., Bartunek J., Bonnier J., de Bruyne B., Eberli F.R., Erne P., Haude M., Heublein B., Horrigan M., Ilsley C., Böse D., Koolen J., Lüscher T.F., Weissman N., Waksman R. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet, 2007; 369: 1869–1875. doi: 10.1016/S0140-6736(07)60853-8
20. Haude M., Erbel R., Erne P., Verheye S., Degen H., Vermeersch P., Wijnbergen I., Weissman N., Prati F., Waksman R., Koolen J. Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. EuroIntervention, 2016; 12: e160–e166. doi: 10.4244/EIJ-D-15-00371
21. Haude M., Ince H., Toelg R., Lemos P.A., von Birgelen C., Christiansen E.H., Wijns W., Neumann F.J., Eeckhout E., Garcia-Garcia H.M., Waksman R. Safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo coronary lesions: three-year clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. EuroIntervention, 2020; 15: e1375–e1382. doi: 10.4244/EIJ-D-18-01000
22. Verheye S., Wlodarczak A., Montorsi P., Bennett J., Torzewski J., Haude M., Vrolix M., Buck T., Aminian A., Schaaf R.J., Nuruddin A.A., Lee M.K.Y. Twelve-month outcomes of 400 patients treated with a resorbable metal scaffold: insights from the BIOSOLVE-IV registry. EuroIntervention, 2020; 15: e1383–1386. doi: 10.4244/EIJ-D-18-01058
23. Zheng J.F., Qiu H., Tian Y., Hu X.Y., Luo T., Wu C., Tian Y., Tang Y., Song L., Li Li L., Xu L., Xu B., Gao R. Preclinical evaluation of a novel sirolimus-eluting iron bioresorbable coronary scaffold in porcine coronary artery at 6 months. JACC Cardiovasc. Interv., 2019; 12: 245–255. doi: 10.1016/j.jcin.2018.10.020
24. Qi Y., Qi H., He Y., Lin W., Li P., Qin L., Hu Y., Chen L., Liu Q., Sun H., Liu Q., Zhang G., Cui Sh., Hu J., Yu L., Zhang D., Ding J. Strategy of metal-polymer composite stent to accelerate biodegradation of iron-based biomaterials. ACS Appl. Mater. Interfaces., 2018; 10: 182–192. doi: 10.1021/acsami.7b15206
25. Vahl T.P., Gasior P., Gongora C.A., Ramzipoor K., Lee C., Cheng Y., McGregor J., Shibuya M., Estrada E.A., Conditt G.B., Kaluza G.L., Granada J.F. Four-year polymer biocompatibility and vascular healing profile of a novel ultrahigh molecular weight amorphous PLLA bioresorbable vascular scaffold: an OCT study in healthy porcine coronary arteries. Euro-Intervention, 2016; 12: 1510–1518. doi: 10.4244/EIJ-D-16-00308
26. Jinnouchi H., Torii S., Sakamoto A., Kolodgie F.D., Virmani R., Finn A.V. Fully bioresorbable vascular scaffolds: lessons learned and future directions. Nat. Rev. Cardiol., 2019; 16: 286–304. doi: 10.1038/s41569-018-0124-7
27. Lv X., Shen L., Wu Y., Ge L., Chen J., Yin J., Wang R., Ji M., Hong B., Ge J. Healing score of the Xinsorb scaffold in the treatment of de novo lesions: 6-month imaging outcomes. Int. J. Cardiovasc. Imaging., 2018; 34: 1009–1016. doi: 10.1007/s10554-018-1326-0
Review
For citations:
Zagorulko A.I., Chernyaev M.V., Koledinskiy A.G. Bioresorbable scaffolds: past and present. Clinical example of a 10-year follow-up of a patient with an implanted Absorb stent. Ateroscleroz. 2024;20(2):173-182. (In Russ.) https://doi.org/10.52727/2078-256X-2024-20-2-173-182
Views:
186
Email this article 